Emcure Pharmaceuticals Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| EMCURE.NS | GRANULES.BO | 003220.KS | TAK | TEVA | MOREPENLAB.NS | |
|---|---|---|---|---|---|---|
| Market cap | 425.90B | 192.80B | 172.75B | 67.28B | 48.83B | 53.21B |
| P/E (TTM) | 39.0 | 35.3 | — | 300.9 | 97.3 | 28.3 |
| Forward P/E | 27.9 | 26.5 | — | 39.7 | 13.4 | — |
| Price/book | 8.0 | 4.8 | — | 1.4 | 6.1 | 3.9 |
| Dividend yield | 0.17% | 0.26% | 3.11% | 2.93% | — | 0.20% |
| 1-year change | +58.97% | +0.63% | −38.51% | +54.40% | +71.10% | +113.46% |
| Today | +3.92% | −0.01% | +0.37% | +1.49% | −0.14% | −4.17% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.
Latest news
All EMCURE.NS news ›Emcure Pharmaceuticals Reports 24% Revenue Growth and 29% Rise in PAT in Q2 FY27
Emcure Pharmaceuticals Limited (BSE: 544210, NSE: EMCURE) has reported a strong financial performance for the second quarter ended September 30, 2026, with consolidated revenue from operations increasing 24.3% year-on-year to ₹28,205…
More from 1 other outlet
Strong Momentum Meets Stretched Valuations as Emcure Pharmaceuticals Ltd Reaches All-Time High
Strong Price Momentum and Market Outperformance On 04 Nov 2026, Emcure Pharmaceuticals Ltd’s stock surged by 8.15% in a single day, substantially outperforming the Sensex, which gained a modest 0.59%. The stock opened with a gap up of…
Emcure Pharmaceuticals approves merger of two wholly-owned subsidiaries
Emcure Pharmaceuticals Ltd on Monday said its board of directors has approved merger of two of its wholly-owned subsidiaries Zuventus Healthcare Ltd and Emcutix Biopharmaceuticals Ltd with the holding company. The amalgamation aims to…
More from 1 other outlet
Emcure Pharmaceuticals board approves draft merger scheme with Zuventus Healthcare and Emcutix Biopharmaceuticals
The scheme was approved at a board meeting held on October 12, 2026. Under the proposed arrangement, both subsidiaries will be merged with Emcure Pharmaceuticals, subject to the necessary statutory and regulatory approvals. The proposed…
Gilead Sciences, Inc. Expands Royalty-Free Voluntary Licensing Agreements For Lenacapavir With Dr. Reddy?s Laboratories Limited, Emcure Pharmaceuticals Limited, Eva Pharma For Pharmaceutical Industries S.A.E., Ferozsons Laboratories Limited, Hetero And Mylan Laboratories Limited
Gilead Sciences, Inc. announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV... announced that it has expanded the scope of…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- businessupturn.com1
- marketscreener.com1
- money.rediff.com1
- news18.com1
- studycafe.in1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.